Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Creatine lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Muscle Marketing USA, which distributes Creatine Serum, files $150 mil. lawsuit July 3 against Degussa Bioactives for unlawful and unfair business practices, false advertising and unlawful concealment of facts relating to the firm's Creapure powder. MMUSA alleges Degussa's ads misrepresent facts about creatine by telling consumers Creapure is safe, "even though it is associated with ailments ranging from stomach cramps to dehydration." Firm further contends that since 1999, Degussa "has repeatedly attempted to misappropriate information about the chemical formulation and nature of Creatine Serum," which is a liquid form of creatine marketed to athletes. 1MMUSA's Web site maintains Creatine Serum is safer than powders because small doses "have the equivalent benefits of large amounts of powder"...

You may also be interested in...



GNC creatine serum

Muscle Marketing USA objects to GNC marketing "shoddy imitation" of its Creatine Serum that "does not contain creatine phosphate complex" or absorb as easily into the body. In an Aug. 4 release, the Los Angeles-based firm insists GNC either rename the copycat product "or face legal action." GNC has agreed to change the name of its creatine product "as soon as their current inventory is exhausted," MMUSA reports. The firm filed a $150 mil. lawsuit against Degussa Bioactives for falsely advertising the safety of its Creapure creatine powder in July (1"The Tan Sheet" July 7, 2003, In Brief)....

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel